

Table of Contents

1
1
1

<u>Table of Contents</u>	<u>Page No.</u>
1. Executive Summary of Procter & Gamble Recommendations	6
2. Responses to Questions/Comments Raised by the Agency	9
2.A. Plaque Reduction Labeling for Actives that do not Reduce Plaque	11
2.B. OTCness of Antigingivitis Agents that do not Reduce Plaque	18
2.C. Comments on Combination Products	22
2.D. Data on Performance Tests	27
2.D.1. Plaque Glycolysis and Regrowth Model (PGRM) for SnF ₂ and CPC	29
2.D.1.1. Scientific Basis of PGRM	29
2.D.1.2. Statistical Methods for the PGRM Test	30
2.D.1.3. Proposed Effectiveness Requirements	33
2.D.1.4. Reference Product for PGRM Test	35
2.D.2. Disk Retention Assay (DRA) for CPC	36
2.D.2.1. Scientific Basis of DRA Test	36
2.D.2.2. DRA Performance Test Method	38
2.D.2.3. Effectiveness Criteria for DRA Performance Test	39
2.D.2.4. Reference Standard for DRA Testing	41
3. New Data and Comments on Stannous Fluoride (SnF ₂)	42
3.A. SnF ₂ formulations are effective in reducing plaque mass, plaque virulence, and plaque composition	43
3.A.1. Literature Studies	45
3.A.1.1. Two 6-month Plaque/Gingivitis Clinical Studies	46
3.A.2. Procter & Gamble Studies	49
3.A.2.1. 6-month Plaque/Gingivitis Clinical Study	50
3.A.2.2. Experimental Gingivitis Study	52
3.A.2.3. Digital Plaque Imaging Analysis Repeated Measures (DPIARM) Study	56
3.A.2.4. Summary of SnF ₂ Antiplaque Results and Recommendations	63

<u>Table of Contents</u>	<u>Page No.</u>
3.B. Microbiology studies demonstrating that SnF ₂ has broad spectrum antimicrobial activity against gingivitis organisms	64
3.B.1. Time Kill Study	65
3.B.2. Minimum Bactericidal Dilution (MBD) Analysis	67
3.B.3. Oral Biofilm Inhibitory Properties	69
3.B.4. Vital Staining Study	71
3.B.5. Summary of SnF ₂ Antibacterial Results and Recommendations	72
4. New Data and Comments on Cetylpyridinium Chloride (CPC)	73
4.A. Microbiological studies demonstrating that CPC has broad spectrum antimicrobial activity against gingivitis organisms	73
4.A.1. Time Kill Study	74
4.A.2. Minimum Inhibitory Dilution (MID)/Minimum Bactericidal Dilution (MBD) Analysis	76
4.A.3. Oral Biofilm Inhibitory Properties	78
4.A.4. Vital Staining Study	79
4.A.5. <i>In vivo</i> Salivary Germ Kill Test	80
4.A.6. Summary of CPC Antibacterial Results and Recommendations	81
5. General Monograph Considerations and Labeling	82
5.A. Cosmetic Plaque Claims	82
5.A.1. Intended Use	83
5.A.2. Qualification of Cosmetic Benefits	85
5.B. Alternative Topical Oral Dose Forms	89
5.C. Recommendations for Revisions in the Labeling of OTC Antigingivitis/Antiplaque Drug Products	95

Table of Contents	Page No.
5.C.1. Indications/uses	95
5.C.1.1. Indications/uses Should be Broadened to Allow Multiple Description of Drug Action	96
5.C.2. Warnings	100
5.C.3. Drug Facts Labeling – Summarized	103
5.D. Professional Labeling	107
5.E. Clinical Significance in Gingivitis Trials – Supporting Rationale and Recommendations	109
5.E.1. Framework to Judge Significance	110
5.E.2. “Weight of Evidence”	111
5.E.2.1. Statistically Significant Reduction in Gingivitis	111
5.E.2.2. Site Specific Analysis	111
5.E.3. Weight of Evidence Utilized but Not Appropriate for Monograph	114
5.E.4. Proportional Reduction Analysis	115
5.E.4.1. Proportional Reduction Appropriate Analysis for Monograph	115
5.E.5. Future Research Needed	119